Bio-Rad Laboratories (NYSE:BIO) Releases Earnings Results, Beats Estimates By $0.04 EPS

Bio-Rad Laboratories (NYSE:BIO) posted its earnings results on Thursday. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.04, Zacks reports. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories updated its FY 2025 guidance to EPS.

Bio-Rad Laboratories Stock Down 7.2 %

Shares of BIO stock traded down $22.18 during midday trading on Friday, reaching $284.18. 307,190 shares of the stock were exchanged, compared to its average volume of 172,294. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The firm has a market cap of $7.96 billion, a PE ratio of -10.40 and a beta of 0.90. The company’s 50 day moving average is $339.70 and its two-hundred day moving average is $336.52. Bio-Rad Laboratories has a 1 year low of $262.12 and a 1 year high of $387.99.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on BIO shares. Wells Fargo & Company dropped their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a report on Wednesday. StockNews.com upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, Citigroup lifted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Bio-Rad Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.